<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717310</url>
  </required_header>
  <id_info>
    <org_study_id>RSJ10431</org_study_id>
    <nct_id>NCT04717310</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis</brief_title>
  <acronym>MARBLE-23</acronym>
  <official_title>A Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult and Adolescent Patients With Mild-to-Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reistone Biopharma Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reistone Biopharma Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase&#xD;
      II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult and&#xD;
      Adolescent Patients with Mild-to-Moderate Atopic Dermatitis.&#xD;
&#xD;
      It will consist of phase II and phase III parts, phase II will be a dose-ranging part and&#xD;
      phase III will be a pivotal study part.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the topical SHR0302 ointment, a JAK (Janus Kinase) inhibitor, in&#xD;
      atopic dermatitis patients. The EASI (Eczema Area and Severity Index), IGA (immunoglobulin&#xD;
      A), SCORAD (Scoring of Atopic Dermatitis),DLQI (Dermatology Life Quality Index)and NRS&#xD;
      (Numeric Rating Score) will be applied to assesses to the efficacy, and other safety&#xD;
      measurements will be also collected within the whole study duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline in the eczema area and severity index (EASI) total score at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The percentage of subjects achieving the Investigator's Global Assessment（IGA）of clear (0) or almost clear (1) with a ≥2 points improvement from baseline at Week 8</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">461</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Active Comparator: SHR0302 Ointment Dose#1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: SHR0302 Ointment Twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: SHR0302 Ointment Dose#2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: SHR0302 Ointment Twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: SHR0302 Ointment Dose#3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: SHR0302 Ointment Twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Vehicle Twice a day (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302 Ointment</intervention_name>
    <description>SHR0302 Ointment Twice a day (BID)</description>
    <arm_group_label>Active Comparator: SHR0302 Ointment Dose#1</arm_group_label>
    <other_name>SHR0302 Ointment 2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302 Ointment</intervention_name>
    <description>SHR0302 Ointment Twice a day (BID)</description>
    <arm_group_label>Active Comparator: SHR0302 Ointment Dose#2</arm_group_label>
    <other_name>SHR0302 Ointment 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302 Ointment</intervention_name>
    <description>SHR0302 Ointment Twice a day (BID)</description>
    <arm_group_label>Active Comparator: SHR0302 Ointment Dose#3</arm_group_label>
    <other_name>SHR0302 Ointment 0.5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Twice a day (BID)</description>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject at ≥12 years of age at time of informed consent.&#xD;
&#xD;
          -  Have mild-to- moderate AD (Atopic Dermatitis), as determined by all of the following:&#xD;
&#xD;
               1. Were diagnosed with AD (defined by the Hanifin and Rajka criteria)&#xD;
&#xD;
               2. With AD history at least 6 months&#xD;
&#xD;
          -  Capable of providing a signed and dated informed consent form indicating the subject&#xD;
             has been informed of all pertinent aspect of the study&#xD;
&#xD;
          -  All women of childbearing potential and all men must be willing to use at least one&#xD;
             highly effective method of contraception from signing of informed consent, throughout&#xD;
             the duration of the study, and for 28 days after last dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects currently have active forms of other skin disease (e.g., psoriasis, or lupus&#xD;
             erythematosus) that would interfere with evaluation of the effect of study medication&#xD;
             on atopic dermatitis, or skin infections (bacteria, fungi, or viruses), or diseases&#xD;
             that can cause skin itching (such as itching caused by diabetes), or subjects who are&#xD;
             allergic to topical skin drugs&#xD;
&#xD;
          -  Subjects with serious concomitant illness that could require administering of systemic&#xD;
             corticosteroids or otherwise interfere with study participation or require active&#xD;
             frequent monitoring (e.g. unstable chronic asthma)&#xD;
&#xD;
          -  Subjects who have a history of mental illness or disease such as anxiety and&#xD;
             depression, and are not suitable to participate in this study&#xD;
&#xD;
          -  Subjects with serious and uncontrolled disease that may affect the safety of the&#xD;
             subject, compliance, affect the evaluation of the endpoint, or require the use of&#xD;
             drugs that are not allowed in the protocol&#xD;
&#xD;
          -  Subjects with Human immunodeficiency virus (HIV), or hepatitis B virus ,or hepatitis C&#xD;
             virus ,or syphilis related laboratory test positive (subjects positive for hepatitis B&#xD;
             surface antigen, HBV (hepatitis B virus) DNA must be greater than or equal to 500&#xD;
             copies/ml)&#xD;
&#xD;
          -  Subjects with malignant tumors or a history of malignant tumors, except for fully&#xD;
             treated or resected skin non-metastatic basal cell carcinoma or squamous cell&#xD;
             carcinoma&#xD;
&#xD;
          -  Pregnant female subjects, breastfeeding female subjects, or male subjects able to&#xD;
             father children and female subjects of childbearing potential who are unwilling or&#xD;
             unable to use a highly effective method of contraception as outlined in protocol for&#xD;
             the duration of the study and for at least 28 days after last dose of investigational&#xD;
             product.&#xD;
&#xD;
          -  The investigators determined that there were conditions that affected the safety and&#xD;
             efficacy of the investigational drug&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator or Reistone, will be unsuitable for&#xD;
             inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lingyu Guo</last_name>
    <phone>847.293.7866</phone>
    <email>lingyu.guo@reistonebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imran Ghiasuddin</last_name>
    <phone>847.293.7866</phone>
    <email>imran.ghiasuddin@reistonebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linfeng Li</last_name>
      <email>zoonli@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chongqing Traditional Chinese Medicine Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital Affiliated to AMU (Southwest Hospital)</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital of AMU</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chao Ji</last_name>
      <email>surpassing_ji@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatology Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Skin Disease Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yangfeng Dong</last_name>
      <email>dingyangfeng@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Litao A Zhang</last_name>
      <email>zhanglitao@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SIR RUN RUN Shaw Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao Cheng</last_name>
      <email>hzchenghao@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hwa Mei Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiangyu Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun. Yat- Sen Memorial Hospital, Sun. Yat- Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qing Guo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang province People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Tao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated To Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quan Chao</last_name>
      <email>drquanchao@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

